Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sorafenib.

Ahmed A Abdelgalil1, Hamad M Alkahtani2, Fahad I Al-Jenoobi2

  • 1Central Laboratory, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|April 29, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Burden and Impact of Drug Shortages in a Saudi Tertiary Hospital: A Single-Center Cross-Sectional Survey.

Healthcare (Basel, Switzerland)·2026
Same author

Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.

Experimental biology and medicine (Maywood, N.J.)·2026
Same author

Multi-target therapeutic potential of Neem (<i>Azadirachta indica</i>) phytochemicals in Alzheimer's disease: an integrative network pharmacology and molecular dynamics simulation approach.

In silico pharmacology·2025
Same author

Drug Interaction of Dasatinib with Thymoquinone: A Pharmacokinetic Study in Rats.

International journal of medical sciences·2025
Same author

Indazol-Pyrimidine Hybrids: Design, Synthesis, and Antiproliferative Activity Against Human Cancer Cell Lines.

Molecules (Basel, Switzerland)·2025
Same author

Mitigating Cadmium Toxicity: The Therapeutic Potential of Lactobacillus acidophilus Pro4 in Mice.

Probiotics and antimicrobial proteins·2025

This study profiles sorafenib, an anticancer drug, detailing its chemical properties, analytical methods, and pharmacology. It highlights the need for improved methods to quantify sorafenib degradation products in pharmaceutical formulations.

Area of Science:

  • Pharmaceutical Chemistry
  • Oncology
  • Analytical Chemistry

Background:

  • Sorafenib (Nexavar®) is an FDA-approved anticancer drug for hepatocellular carcinoma and renal cell carcinoma.
  • It functions by inhibiting tumor growth and angiogenesis via the RAF/MEK/ERK pathway and receptor tyrosine kinases.

Purpose of the Study:

  • To provide a comprehensive profile of sorafenib.
  • To review analytical methods for its characterization and quantification.
  • To assess existing stability-indicating methods and identify gaps in degradation product analysis.

Main Methods:

  • Detailed review of sorafenib's nomenclature, formula, elemental analysis, preparation, and physicochemical properties.
  • Analysis of spectroscopic (UV/vis, vibrational, NMR, MS) and chromatographic (TLC, HPLC) methods.
Keywords:
Cancer drugClinical usesComprehensive profileDrug-drug interactionsHepatocellular carcinomaPharmacologySorafenibTyrosine kinase inhibitors

Related Experiment Videos

  • Examination of pharmacodynamics, pharmacokinetics, and drug-drug interactions.

    • Main Results:

    • A thorough compilation of sorafenib's chemical and analytical data.
    • Identification of limited stability-indicating methods for sorafenib quantification.
    • Lack of methods specifically designed to separate and quantify sorafenib degradation products.

    Conclusions:

    • Sorafenib is a crucial targeted therapy with a well-defined mechanism of action.
    • Current analytical methods require enhancement, particularly for stability studies and degradation product analysis.
    • Further research is needed to develop robust methods for comprehensive sorafenib stability assessment.